Short interest in Indaptus Therapeutics Inc (NASDAQ:INDP) decreased during the last reporting period, falling from 119.93K to 81.07K. This put 0.71% of the company's publicly available shares short.

Indaptus Therapeutics INDP announced positive data from pre-clinical studies that demonstrated the efficacy of Decoy, its bacteria-based immunotherapy platform technology. The data was presented in a ...

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative ...

On Tuesday, Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced it advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. The expansion will evaluate the combination of Decoy20 ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Indaptus Therapeutics Inc. (INDP) announced on Monday that it has secured a $6 million investment through the sale of non-voting convertible preferred stock to investor David E. Lazar. Following the ...

Indaptus Therapeutics ( (INDP)) has issued an update. On January 8, 2026, Indaptus Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed David Natan as a Class II ...

) has been revised to $10.20 / share. This is a decrease of 60.00% from the prior estimate of $25.50 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral ...